Pharmacological Blockade of LPAR1 Does Not Provide Neuroprotection in a Rat Model of Ocular Hypertensive Glaucoma
Translational Vision Science & Technology · 2026
DOI: 10.1167/tvst.15.1.11 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Vision Science & Technology, 2026. Verfasst von Sai Kocherlakota und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Neuroscience, Division of Eye and Vision, St. Erik Eye Hospital, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Neuroprotection, Receptors, Lysophosphatidic Acid, Glaucoma, Retinal Degeneration. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Purpose
Current treatment strategies for glaucoma, the leading cause of irreversible blindness, only target intraocular pressure (IOP) but not the underlying retinal ganglion cell degeneration. IOP management is not always effective, necessitating neuroprotective strategies. Lysophosphatidic acid (LPA) is an extracellular signaling molecule implicated in modulating inflammation. It exerts its signaling effects through its receptors (LPAR1-6). Here we test the efficacy of PIPE-791, an LPAR1-selective antagonist, in conferring neuroprotection and modulating neuroinflammation in glaucoma.
Methods
A bead-induced rat ocular hypertension (OHT) model of glaucoma was used to test PIPE-791 (administered intraperitoneally at 3 mg/kg dosing). We monitored IOP through tonometry and evaluated PIPE-791's neuroprotective capacity by studying retinal ganglion cell survival using cell counting and its effects on retinal vasculature, immune cell numbers and cytokine profile.
Results
PIPE-791 had no effect on IOP in normotensive (NT) or OHT rat eyes. It also did not have any neuroprotective effect on retinal ganglion cell survival, nor did it normalize the changes in retinal vasculature observed in OHT retinas. Although PIPE-791 treatment increased microglial numbers in NT retinas, there was no effect in OHT retinas. Cytokine array profiling also revealed no significant effects for PIPE-791 on the cytokine changes between the NT and OHT retinas. These lack of changes could potentially be explained by the fact that LPAR1 protein levels are decreased in OHT retinas.
Conclusions
Our data suggests that targeting LPAR1 through pharmacological means does not provide neuroprotection or modulate neuroinflammation favorably in glaucoma. Translational Relevance: Our study provides evidence that pharmacological targeting of LPAR1 as a potential therapeutic avenue in glaucoma may not be beneficial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Neuroscience, Division of Eye and Vision, St. Erik Eye Hospital, Karolinska Institutet, Stockholm, Sweden.
- Contineum Therapeutics, San Diego, CA, USA.
- Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.
Zitieren
APA
Kocherlakota, S., Nicol, A., Locri, F., Stebbins, K. J., Lorrain, D. S., Tribble, J. R., & Williams, P. A. (2026). Pharmacological Blockade of LPAR1 Does Not Provide Neuroprotection in a Rat Model of Ocular Hypertensive Glaucoma. Translational Vision Science & Technology. https://doi.org/10.1167/tvst.15.1.11
Vancouver
Kocherlakota S, Nicol A, Locri F, Stebbins KJ, Lorrain DS, Tribble JR, et al. Pharmacological Blockade of LPAR1 Does Not Provide Neuroprotection in a Rat Model of Ocular Hypertensive Glaucoma. Translational Vision Science & Technology. 2026. doi:10.1167/tvst.15.1.11
BibTeX
@article{Kocherlakota2026,
author = {Kocherlakota, Sai and Nicol, Alan and Locri, Filippo and Stebbins, Karin J and Lorrain, Daniel S and Tribble, James R and Williams, Pete A},
title = {Pharmacological Blockade of LPAR1 Does Not Provide Neuroprotection in a Rat Model of Ocular Hypertensive Glaucoma},
journal = {Translational Vision Science & Technology},
year = {2026},
doi = {10.1167/tvst.15.1.11}
}
EUVIMED